Anxiety and Depression In Patients With Obstructive Sleep Apnoea Before and After Continuous Positive Airway Pressure (ADIPOSA)

University of Granada (UGR)

Status: Completed

Conditions: Obstructive Sleep Apnea

Treatments: Device: Continuous positive airway pressure (CPAP)

Study type: Interventional

Funder types: Other

Identifiers

NCT04104880

ADIPOSA-19

Details and patient eligibility

About

Continuous positive airway pressure (CPAP) is the gold-standard treatment for obstructive sleep apnoea (OSA), the most common sleep-disordered breathing in the overall population. CPAP has shown to be effective in reducing apnoea-hypopnoea index (AHI) as well as other OSA polysomnographic outcomes. However, the effectiveness of this device on OSA daily functioning and mood disturbances outcomes still remains unclear. The ADIPOSA study is aimed at determining the effects of three-month CPAP use on anxiety-depression symptoms in patients with OSA. Participants will be adults previously diagnosed with OSA who will be allocated to a CPAP-treatment group. Outcomes will be measured at baseline and intervention end-point (three months) including daytime sleepiness, daily functioning and mood (anxiety and depression symptoms), AHI, other neurophysical and cardiorespiratory polysomnographic outcomes, and body weight. ADIPOSA may serve to establish the effectiveness of CPAP on daytime functioning and mood disturbances commonly found on patients with OSA and, in turn, on other OSA outcomes related to anxiety-depression symptoms.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previous clinical diagnosis of mild/moderate/severe OSA (AHI > 5) by a healthcare professional
• Use of CPAP
• Motivation to participate in the study
• Willing to provide informed consent

Exclusion criteria

• Presence of any other primary sleep disorder
• Presence of any mental disorder (including depression, anxiety, and addiction to alcohol or other substances)
• Presence of any other severe organic disease, except for those comorbid to OSA

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Continuous Positive Airway Pressure (CPAP) group

Experimental group

Description:

Three-month CPAP use

Treatment:

Device: Continuous positive airway pressure (CPAP)